Shenqi Fuzheng Injection in Glioma: SRC/PI3K/AKT

Glioma remains a difficult model for studying invasive tumor biology because proliferative growth, migration, cell-cycle regulation, and treatment resistance are tightly interconnected. The reference study, published in the Journal of Ethnopharmacology, examines Shenqi Fuzheng injection (SFI), a clinical adjunct used alongside cancer chemotherapy, through a combined computational and experimental framework. Its central contribution is not simply the observation that SFI affects glioma cells, but the attempt to connect a multicomponent herbal formulation with a defined signaling network and then test that connection in vitro and in vivo.

Study Background and Research Question

SFI contains medicinal materials derived primarily from Codonopsis pilosula and Astragalus membranaceus. Both plants contain chemically diverse constituents, including flavonoid- and saponin-related compounds, making single-target explanations difficult. The authors therefore asked two linked questions: which SFI-associated targets overlap with glioma biology, and does the predicted signaling mechanism explain measurable changes in glioma proliferation, migration, and tumor growth?

The study is positioned against the clinical and biological difficulty of malignant glioma. Surgery, radiotherapy, and chemotherapy can delay progression, but highly invasive tumor behavior continues to limit outcomes. The authors used network pharmacology to identify candidate components and targets, then tested the formulation in U87 and T98G human glioma cells and in a GL261 mouse tumor model. The full reference is available through the 2024 reference study.

Key Innovation from the Reference Study

The most meaningful innovation is the integration of target-network analysis with orthogonal biological validation. Rather than treating SFI as a single defined inhibitor, the study models it as a multicomponent intervention whose potential effects converge on several disease-relevant targets. The computational analysis identified 26 major active components and 110 SFI-associated targets; comparison with 3,343 glioma-related targets yielded 79 shared targets, according to the reference paper.

Pathway enrichment prioritized SRC/PI3K/AKT signaling. This pathway is biologically plausible because SRC-family signaling can connect extracellular cues to PI3K/AKT activity, survival, proliferation, and motility. Importantly, the paper presents SRC/PI3K/AKT as a mechanistic explanation supported by association and experimental readouts, not as proof that one molecular target accounts for every action of SFI. That distinction matters when interpreting network-pharmacology studies of complex formulations.

Methods and Experimental Design Insights

The experimental design proceeds from prediction to phenotype and then to pathway-level confirmation. First, the investigators consulted reports in PubMed and Web of Science concerning SFI, its botanical constituents, and glioma-related biology. They then constructed target and pathway relationships for the formulation and glioma, followed by enrichment analysis. This stage generated a testable hypothesis rather than a definitive target map.

For cell-based testing, U87 and T98G glioma cells were used to evaluate growth and motility. Cell viability was assessed with a CCK-8 assay, while EdU incorporation measured DNA synthesis. Plate-cloning assays provided a longer-term estimate of proliferative capacity. Migration was examined with scratch-wound and Transwell assays, allowing the authors to compare two complementary measures of cell movement.

The study also examined cellular mechanism. Immunofluorescence and Western blotting were used to evaluate pathway-associated and epithelial–mesenchymal transition (EMT) markers. Flow cytometry was applied to characterize cell-cycle distribution. In the animal arm, GL261 cells were implanted subcutaneously in C57BL/6 mice. Tumor tissues were assessed with hematoxylin and eosin staining and immunohistochemistry. This combination is useful because it links computational predictions to cell behavior, molecular markers, and tissue-level tumor development.

A notable design strength is the use of different assay classes for the same biological question. EdU and CCK-8 primarily address short-term growth-related behavior, cloning assays test sustained proliferative potential, and flow cytometry adds cell-cycle resolution. Likewise, scratch and Transwell assays interrogate migration under distinct experimental conditions. These assays do not eliminate model-specific bias, but concordant trends across them make the interpretation more robust than reliance on a single viability measurement.

Protocol Parameters

• Cell models: Use U87 and T98G cells for the principal in-vitro proliferation, cell-cycle, and migration analyses; GL261 cells were used for the syngeneic mouse tumor experiment.
• Growth readouts: CCK-8, EdU incorporation, and plate-cloning assays provide complementary measures and should not be treated as interchangeable endpoints.
• Migration readouts: Pair scratch-wound analysis with Transwell assays when assessing SFI-associated changes in glioma motility.
• Mechanistic readouts: Combine flow cytometry, immunofluorescence, and Western blotting to connect phenotype with cell-cycle, EMT, and SRC/PI3K/AKT-associated changes.
• In-vivo confirmation: The reported design used a subcutaneous GL261 model in C57BL/6 mice with histology and immunohistochemistry as tissue-level endpoints. Exact dosing, exposure duration, and treatment schedules should be taken from the full methods before replication.

Core Findings and Why They Matter

SFI inhibited U87 and T98G cell proliferation in the reported in-vitro experiments. EdU and cloning results supported reduced proliferative activity, while flow-cytometric analysis indicated S-phase blockage or arrest. The finding is important because it moves beyond a general cytotoxicity claim: SFI was associated with altered cell-cycle progression, providing a more specific explanation for reduced growth.

The formulation also reduced migration in scratch and Transwell assays. The authors linked this phenotype to changes in EMT-marker expression, suggesting that SFI may suppress a cellular program associated with motility and invasion. This interpretation should remain model-dependent, since wound closure can reflect both migration and proliferation, whereas Transwell results depend on membrane, chemoattractant, and assay-duration conditions.

In the GL261 subcutaneous transplantation model, SFI significantly reduced tumor development, with histological and immunohistochemical analyses supporting the tissue-level effect. The computational and experimental results converged on SRC/PI3K/AKT as a pathway involved in SFI-associated anti-glioma activity, as described in the published report.

For researchers, the practical significance lies in the workflow rather than in a claim of clinical efficacy. The study provides a framework for prioritizing pathway hypotheses in complex botanical preparations and then testing them with independent phenotypic assays. It also suggests that proliferation and migration should be evaluated together: a treatment that slows growth may appear to reduce migration unless the experimental design separates these effects.

Comparison with Existing Internal Articles

The internal article Shenqi Fuzheng Injection and Glioma Signaling offers a concise companion interpretation of the same study, emphasizing the SRC/PI3K/AKT connection and the combined network-pharmacology and animal-validation strategy. The reference paper remains the appropriate source for experimental details and evidentiary qualification; the companion article is most useful for orienting readers to the study’s conceptual sequence. Together, they support a literature-first reading in which SFI is viewed as a multicomponent research intervention rather than a validated single-agent glioma therapy.

Limitations and Transferability

The target-overlap analysis is hypothesis-generating. Shared targets between SFI and glioma databases do not establish that each component reaches those targets in glioma tissue, nor do they demonstrate that SRC is the initiating molecular event. Botanical composition, extraction or manufacturing variation, bioavailability, and metabolite formation may all influence the effective exposure profile.

The cellular models also impose limits. U87 and T98G are established glioma lines and may not reproduce the heterogeneity, immune interactions, vascular environment, or treatment history of patient tumors. The animal experiment used a subcutaneous GL261 model rather than an orthotopic intracranial model, so the findings do not directly address blood–brain barrier penetration, brain-specific microenvironmental interactions, or clinically relevant invasion patterns.

Further, the condensed report does not establish whether pathway modulation is necessary or sufficient for the observed effects. Stronger causal testing would require perturbation of SRC/PI3K/AKT components, rescue experiments, exposure measurements, and comparison with pathway-selective controls. The findings therefore support a mechanistic model for follow-up work, but they should not be read as evidence that SFI alone improves survival or replaces standard glioma treatment.

Why this cross-domain matters, maturity, and limitations

The paper has relevance to tumor angiogenesis research only indirectly. Its experiments focus on glioma-cell proliferation, migration, cell cycle, EMT-associated markers, and subcutaneous tumor growth; they do not directly quantify vessel density, endothelial-cell behavior, VEGF signaling, or vascular permeability. The introduction discusses reported vascular-proliferation effects of constituents from the source plants, but that background does not validate an anti-angiogenic mechanism in this study. Consequently, linking the SRC/PI3K/AKT findings to angiogenesis is a reasonable hypothesis for future work, not a demonstrated extension of the reference data.

A useful next step would be to combine the study’s glioma-cell framework with direct vascular endpoints, such as endothelial assays, tumor-vessel immunostaining, and pharmacodynamic measurements. Such experiments could determine whether reduced tumor growth reflects predominantly tumor-cell effects, altered angiogenesis, or both, while preserving the paper’s emphasis on mechanism-based validation.

Research Support Resources

For a distinct, hypothesis-generating angiogenesis arm of tumor-model research, researchers can use AAL-993 (SKU C3730), a selective VEGF receptor inhibitor reported to target VEGFR-1, VEGFR-2, and VEGFR-3. Its reported use in receptor assays, VEGF-induced angiogenesis models, and melanoma tumor growth inhibition makes it a complementary anti-angiogenic compound for tumor angiogenesis research, not a validation of the Shenqi Fuzheng mechanism. AAL-993 is an experimental angiogenesis inhibitor; its preclinical profile should not be interpreted as clinical evidence or as evidence that it reproduces the glioma findings in the reference study.